Shilpa Medicare Limited has submitted a regulatory disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015. The disclosure concerns its Unit 4 manufacturing facility located in Jadcherla, Telangana, India.
The unit was subject to an inspection by AGES (Austrian Agency for Health and Food Safety), Austria. The inspection took place over a period of four days, from 27th July 2026 until 30th July 2026.
Following this inspection, the unit has been issued a Good Manufacturing Practice (GMP) certification by AGES, Austria. The certification signifies a successful outcome from the regulatory audit.
The disclosed purpose of the facility is the manufacturing, testing, and distribution of finished dosage forms. Specifically, the unit produces sterile injections and non-sterile tablets and capsules. These products are supplied to markets in Europe and the rest of the world.
The intimation was signed and submitted by Ritu Tiwary, Company Secretary & Compliance Officer of Shilpa Medicare Limited.